急性心肌梗死患者早期不同剂量阿托伐他汀对hs-CRP、血脂水平的影响

目的:探讨不同剂量阿托伐他汀治疗对急性心肌梗死（AMI）患者早期超敏C反应蛋白(hs-CRP)、血脂水平的影响。方法:选取2014年1月~5月入院确诊的AMI患者60例,随机分为20 mg组和40 mg组,每组30例,所有患者入院后均在常规治疗的基础上加用阿托伐他汀,分别给予20 mg和40 mg。比较两组患者入院时和治疗l周后不同剂量对血清hs-CRP、血脂水平的影响。结果:两组治疗前后1周血清hs-CRP、总胆固醇、低密度脂蛋白胆固醇（LDL-C）及高密度脂蛋白胆固醇水平均较入院时显著下降,且40 mg组较20 mg组治疗后LDL-C水平显著下降,两组间差异有统计学意义（P<0.05）。结论:AMI患者早期（1周内）阿托伐他汀治疗对降低hs-CRP、血脂水平有效,并且40 mg组在LDL-C降低幅度上优于20 mg组。

Effect of early use of atorvastatin on hs-CRP and blood lipid levels in patients with acute myocardial infarction

AIM:To explore the effect of different doses atorvastatin treatment on the levels of serum hypersensitive C-reactive protein (CRP) and lipid in patients who were in early acute myocardial infarction (AMI). METHODS: A total of 60 patients with AMI who were hospitalized from January 2014 to May 2014 were randomly divided into 20 mg and 40 mg groups with 30 patients in each group. All patients were administered atorvastatin on the basis of conventional treatment after admission, 20 mg and 40 mg, respectively. We compared the effect on the levels of hs-CRP and lipids in patients of both groups upon hospital admission and after treatment for 1 week with different doses of atorvastatin. RESULTS: Levels of serum hs-CRP, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol in the two groups before and after 1 week treatment were decreased significantly, and the level of LDL-C decreased more significantly in the 40 mg group than in the 20 mg group after treatment, with statistically significant differences between groups (P<0.05). CONCLUSION: Atorvastatin therapy may reduce levels of serum hs-CRP and lipid effectively in early AMI patients (within 1 week), and the reduction of LDL-C in the 40 mg group is more significant than in the 20 mg group.